Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3747450 | 1.00 | ALOX15 (0.58) | ALOX15ALDH1A1CYP3A4TDP1KDM4E | |
| SCHEMBL17923373 | 0.82 | ALDH1A1 (0.60) | ALOX15ALDH1A1CYP3A4TDP1KDM4E | |
| SCHEMBL2857543 | 0.82 | ALDH1A1 (0.60) | ALOX15ALDH1A1CYP3A4TDP1KDM4E | |
| SCHEMBL2857545 | 0.82 | ALDH1A1 (0.60) | ALOX15ALDH1A1CYP3A4TDP1KDM4E | |
| SCHEMBL10379414 | 0.79 | ALDH1A1 (0.50) | ALOX15ALDH1A1CYP3A4TDP1KDM4E | |
| SCHEMBL10556205 | 0.79 | ALDH1A1 (0.50) | ALOX15ALDH1A1CYP3A4TDP1KDM4E | |
| SCHEMBL891912 | 0.77 | ALDH1A1 (0.55) | ALOX15ALDH1A1CYP3A4TDP1KDM4E | |
| SCHEMBL160940 | 0.77 | ALDH1A1 (0.55) | ALOX15ALDH1A1CYP3A4TDP1KDM4E | |
| SCHEMBL160941 | 0.77 | ALDH1A1 (0.55) | ALOX15ALDH1A1CYP3A4TDP1KDM4E | |
| SCHEMBL244549 | 0.77 | ALDH1A1 (0.54) | ALOX15ALDH1A1CYP3A4TDP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4347757-A1 | FRAGRANCE FOR IMPROVING RELAXATION STATE AND METHOD OF ASSESSING | Givaudan SA (CH) | 2024-04-10 | — | — | EP | claimed |
| WO-2022234149-A1 | FRAGRANCE FOR IMPROVING RELAXATION STATE AND METHOD OF ASSESSING | GIVAUDAN SA (CH) | 2022-11-10 | — | — | WO | claimed |
| EP-4688246-A1 | COACERVATE CORE-SHELL MICROCAPSULES | Firmenich SA (CH) | 2026-02-11 | — | — | EP | disclosed |
| EP-4604741-A1 | WAX-BASED MICROCAPSULES | Firmenich SA (CH) | 2025-08-27 | — | — | EP | disclosed |
| US-20250134790-A1 | ANTIMICROBIAL COMPOSITIONS | FIRMENICH SA (CH) | 2025-05-01 | — | — | US | disclosed |
| EP-4387583-A1 | ANTIMICROBIAL COMPOSITIONS | Firmenich SA (CH) | 2024-06-26 | — | — | EP | disclosed |
| WO-2024126683-A1 | COACERVATE CORE-SHELL MICROCAPSULES | FIRMENICH SA (CH) | 2024-06-20 | — | — | WO | disclosed |
| US-20240199524-A1 | INCENSE ODORANT | FIRMENICH & CIE (CH) | 2024-06-20 | — | — | US | disclosed |
| WO-2024083677-A1 | WAX-BASED MICROCAPSULES | FIRMENICH SA (CH) | 2024-04-25 | — | — | WO | disclosed |
| US-20240016727-A1 | LEAVE-ON COMPOSITION | FIRMENICH & CIE (CH) | 2024-01-18 | — | — | US | disclosed |
| US-11744785-B2 | Use of volatile compositions to limit or eliminate the perception of malodor | FIRMENICH SA (CH) | 2023-09-05 | — | — | US | disclosed |
| US-20230233425-A1 | USE OF VOLATILE COMPOSITIONS TO LIMIT OR ELIMINATE THE PERCEPTION OF MALODOR | FIRMENICH SA (CH) | 2023-07-27 | — | — | US | disclosed |
| US-20230105693-A1 | ANTIMICROBIAL COMPOSITIONS | FIRMENICH SA (CH) | 2023-04-06 | — | — | US | disclosed |
| WO-2023020929-A1 | ANTIMICROBIAL COMPOSITIONS | FIRMENICH SA (CH) | 2023-02-23 | — | — | WO | disclosed |
| EP-4106718-A1 | ANTIMICROBIAL COMPOSITIONS | Firmenich SA (CH) | 2022-12-28 | — | — | EP | disclosed |
| US-20200345601-A1 | USE OF VOLATILE COMPOSITIONS TO LIMIT OR ELIMINATE THE PERCEPTION OF MALODOR | FIRMENICH SA (CH) | 2020-11-05 | — | — | US | disclosed |
| US-20140023770-A1 | Use Of Defined Cyclohexenones As Agents For The Superadditive Enhancement Of An Olfactory Impression And Fragrance And/Or Flavor Material Composition | SYMRISE AG (DE) | 2014-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11744785-B2 | Use of volatile compositions to limit or eliminate the perception of malodor | TAS2R8, TRPA1, TAS2R10 | ALOX15 514/4885ALDH1A1 831/4885CYP3A4 145/4885 |
| US-20240199524-A1 | INCENSE ODORANT | OPRM1, CPT1A, TAS2R5 | ALOX15 1098/4885ALDH1A1 392/4885CYP3A4 749/4885 |
| US-20240016727-A1 | LEAVE-ON COMPOSITION | CUTA, DPM1, TYR | ALOX15 51/4885ALDH1A1 506/4885CYP3A4 838/4885 |
| US-20200345601-A1 | USE OF VOLATILE COMPOSITIONS TO LIMIT OR ELIMINATE THE PERCEPTION OF MALODOR | TAS2R8, TRPA1, TAS2R10 | ALOX15 514/4885ALDH1A1 831/4885CYP3A4 145/4885 |
| US-20230233425-A1 | USE OF VOLATILE COMPOSITIONS TO LIMIT OR ELIMINATE THE PERCEPTION OF MALODOR | TAS2R8, TRPA1, TAS2R10 | ALOX15 514/4885ALDH1A1 831/4885CYP3A4 145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.